|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Karyopharm Therapeutics (NASDAQ: KPTI) through any online brokerage.
The latest price target for Karyopharm Therapeutics (NASDAQ: KPTI) was reported by Morgan Stanley on October 12, 2021. The analyst firm set a price target for 27.00 expecting KPTI to rise to within 12 months (a possible 412.33% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Karyopharm Therapeutics (NASDAQ: KPTI) is $5.27 last updated Fri Oct 22 2021 20:00:03 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Karyopharm Therapeutics.
Karyopharm Therapeutics’s $Q3 earnings are confirmed for after-market on $November 5, 2021.
There is no upcoming split for Karyopharm Therapeutics.
Karyopharm Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.